Oncology | Natera

IN THE NEWS

Signatera awarded FDA Breakthrough Device designation for detecting and tracking ctDNA after surgery.

IN THE NEWS

Signatera awarded positive Medicare draft coverage for serial use in stage II & III CRC.


ONCOLOGY

Signatera is the only patient-specific, custom-built circulating tumor DNA (ctDNA) monitoring assay to support cancer treatment planning in early- and
late-stage cancers.


1

Signatera for colorectal cancer (CRC)

The personalized, molecular residual disease (MRD) assessment and surveillance monitoring tool to guide optimal treatment decision-making.

2

Research pipeline

Review our clinical pipeline with leading institutions and biopharmaceutical partners, learn more about our registry studies, or contact us for research services.


IN THE NEWS

Signatera awarded positive Medicare draft coverage for serial use in Stage II & III CRC

Learn More


OUR STORY

For World Cancer Day, core team members from Natera Oncology share their personal stories

Learn More